Metraipolis › archive › dc_2e1407f5ca3d

Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway… — Europe PMC PMID:41079090

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41079090
DOI
10.3389/fonc.2025.1650378
License (as archived)
solo-consultazione
Archived
2026-11-09T18:10:18.127Z
SHA-256 of the archived text
e63a2498144024654f71ec6c356f3a06243f3a65a2fd2f15ddc7b03df7c2bdc0
Stable URL of this page
https://metraipolis.com/documento/dc_2e1407f5ca3d

How to cite

Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway… — Europe PMC PMID:41079090 — Europe PMC (en), https://europepmc.org/article/MED/41079090 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2e1407f5ca3d (Metraipolis archive dc_2e1407f5ca3d, sha256 e63a2498144024654f71ec6c356f3a06243f3a65a2fd2f15ddc7b03df7c2bdc0)
BibTeX
@misc{dc2e1407f5ca3d,
  title = {Time and cost burden associated with docetaxel in patients with metastatic castration-sensitive prostate cancer initiating an androgen receptor pathway… — Europe PMC PMID:41079090},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41079090},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2e1407f5ca3d; sha256 e63a2498144024654f71ec6c356f3a06243f3a65a2fd2f15ddc7b03df7c2bdc0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41079090. Agents can read the archived copy with the MCP tool read_document.